B+
Bull case
25%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
TRDA
Entrada TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The October ENTR-601-45 readout met its primary safety objective, and higher-dose DMD studies plus partnered VX-670 offer multiple ways to improve the clinical thesis. Management expects greater dystrophin production at higher doses, but that remains unproven [#8-K-2026-10-14] SEC Exhibit 99.1.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +15.1.
What can break
Cash declined from $295.7 million at December 31, 2025 to $223.0 million at June 30, 2026; financing or dilution risk rises if spending persists or trials expand [#SEC-10Q-2026-08-05].
Momentum
5
Value
41
Sentiment
65
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.80 · Bull $8.00 · Bear $2.00Analysis 2026-10-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-30 • Vendor: Data Vendor v1
Scores
As of 2026-10-30 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-30
Investment thesis
As of 2026-10-30
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-30. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $17.00
Why
Momentum5 · Δ7d -0.5
Value41 · Δ7d -18.3
Sentiment65 · Δ7d +15.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +15.1.
Contradictions & invalidation
- • Cash declined from $295.7 million at December 31, 2025 to $223.0 million at June 30, 2026; financing or dilution risk rises if spending persists or trials expand [#SEC-10Q-2026-08-05].
- • Higher doses or longer exposure may reveal safety issues; one Cohort 1 participant experienced two serious treatment-emergent adverse events that resolved [#8-K-2026-10-14].
- • The 5 mg/kg cohort was small, its mean dystrophin increase was 0.10%, and no functional benefit was observed.
Catalyst clock
2026-12-31
ENTR-601-44 open-label follow-up
Lead driver: Sentiment · See AI snapshot
Momentum
5
8% active weight
Current posture
7d trendSoftening
Δ7d
-0.5
Δ21d
-4.7
Value
41
47% active weight
Current posture
7d trendSoftening
Δ7d
-18.3
Δ21d
-0.2
Sentiment
65
45% active weight
Current posture
7d trendImproving
Δ7d
+15.1
Δ21d
-11.2
Why this grade
Composite grade D. Momentum 4.9 / Value 40.6 / Sentiment 65.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-17. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$4.80
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.00
Analysis reference price unavailable
Analysis 2026-10-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-30
Fundamentals (TTM)
As of 2026-10-30
Market Cap
$176.58M
Beta
-0.12
Shares Out
38.94M
P/E (TTM) · Derived
-1.3
P/S (TTM)
6.52
P/FCF (TTM) · Derived
-1.41
Rev YoY
-53.9%
EPS YoY
-2.9%
Gross Margin
+21.2%
Op Margin
-3767.1%
Net Debt
-$245.42M
Current Ratio
10.89
As of 2026-10-30 • Updated nightlySource: Internal modelMethods & Data